NICE guidance recommends liraglutide for diabetes19th February 2010
The National Institute for Health and Clinical Excellence has issued its latest draft guidance regarding treatment of diabetes.
It has recommended the use of liraglutide (Victoza), a once-daily injection for the treatment of type 2 diabetes as part of triple therapy regimens.
The body says this latest announcement offers "a new alternative for patients who are unable to control their diabetes with current treatments".
Patients already taking metformin and a sulfonylurea, or metformin and a thiazolidinedione, but still have poor blood glucose control should be offered liraglutide in combination with their current treatments.
Patients must also be overweight, with a body mass index of 35kg/m2 and over, to be eligible for the drug.
However, those below that level could also benefit, says NICE, if it was considered beneficial.
Berkshire GP Dr George Kassianos, who is a member of the British Cardiovascular Society, welcomed the move from a primary care perspective.
He said: “Controlling hyperglycaemia and its indicators is not easy. The addition of liraglutide to our formulary will be welcome by patients and will go a long way to helping them achieve their glycaemic goals.”
Dr Carole Longson, Health Technology Evaluation Centre Director at NICE, said it was not felt there was sufficient evidence to recommend its use in dual therapy regimens for type 2 diabetes mellitus.
“The Committee concluded that there were disparities in the data provided by the manufacturer, particularly regarding the economic analyses of liraglutide in dual therapy regimens for this type of diabetes,” she added.
NICE has invited the manufacturer to respond to those concerns.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: NICE guidance recommends liraglutide for diabetes
Author: Mark Nicholls
Article Id: 14135
Date Added: 19th Feb 2010